After a sold-out conference in 2022, PSYCH Symposium is returning to bring together leading investors, regulators, scientists and industry leaders who are looking to transform the future of healthcare through psychedelic medicine.
The event has become one of the most highly anticipated conferences in the field of psychedelic healthcare, attracting industry leaders and professionals from around the world. The Symposium provides a platform for experts to discuss the latest research, development and commercialisation of psychedelics for various medical conditions.
PSYCH Symposium aims to promote the integration of psychedelics into mainstream medicine, and attendees will have the opportunity to connect with leading researchers in the field, network with peers and learn about the latest developments in psychedelic research and therapy.
The conference will feature keynote speeches from industry leaders, panel discussions and workshops. Topics will range from the latest clinical trials to regulatory updates and investment opportunities in the psychedelics sector.
“The global mental health crisis has quickly transitioned into a global pandemic and we need a solution fast,” said William Potts, Co-Founder of Psych Capital Plc. “We are thrilled to bring PSYCH Symposium back to London where we can host some of the leading minds in the industry who are focused on finding innovative solutions to healthcare that can tackle these issues in the very near future.”
“The field of psychedelic healthcare is rapidly evolving, and we are excited to bring together leading experts to explore the latest developments and discuss how we can integrate psychedelics into mainstream medicine.”
The PSYCH Symposium will take place on 6 July 2023, at The British Museum. Registration is now open and is expected to sell out.
For more information and to register for the event, please visit: www.psychsymposium.com